In a deal valued at $272 million, AZ got exclusive global rights to Ardelyx’s NHE3 program. Pfizer exercised an option to buy spec pharma NextWave for $255 million up front. Biophama companies raised almost $2 billion in October propelled by public offerings. Early venture rounds dominated device financing, which totaled $193 million.
Exhibit 1
Top Alliances In October 2012
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
